Related references
Note: Only part of the references are listed.Methylseleninic acid downregulates hypoxia-inducible factor-1a in invasive prostate cancer
Indu Sinha et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds
John T. Pinto et al.
AMINO ACIDS (2011)
1,4-Phenylenebis(Methylene)Selenocyanate, but Not Selenomethionine, Inhibits Androgen Receptor and Akt Signaling in Human Prostate Cancer Cells
Nicole D. Facompre et al.
CANCER PREVENTION RESEARCH (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Suppression of mTOR via Akt-dependent and -independent mechanisms in selenium-treated colon cancer cells: involvement of AMPKα1
Yun-Kyoung Lee et al.
CARCINOGENESIS (2010)
Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells
Dhimant Desai et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
mTOR Ser-2481 Autophosphorylation Monitors mTORC-specific Catalytic Activity and Clarifies Rapamycin Mechanism of Action
Ghada A. Soliman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics
Bo Dai et al.
BJU INTERNATIONAL (2009)
Selenium enrichment of broccoli sprout extract increases chemosensitivity and apoptosis of LNCaP prostate cancer cells
Rizky Abdulah et al.
BMC CANCER (2009)
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
David A. Guertin et al.
CANCER CELL (2009)
Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer
Weisheng Zhang et al.
CANCER RESEARCH (2009)
Potential Stages for Prostate Cancer Prevention with Selenium: Implications for Cancer Survivors
Nicole Facompre et al.
CANCER RESEARCH (2009)
TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2
Jeremy Copp et al.
CANCER RESEARCH (2009)
Optimal targeting of the mTORC1 kinase in human cancer
Heidi A. Lane et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Effects of Selenite and Genistein on G2/M Cell Cycle Arrest and Apoptosis in Human Prostate Cancer Cells
Rui Zhao et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2009)
Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth
James J. Gibbons et al.
SEMINARS IN ONCOLOGY (2009)
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Nancy Lee et al.
BMC Pharmacology & Toxicology (2009)
Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro
Adam Schayowitz et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Preclinical versus clinical drug combination studies
Ting-Chao Chou
LEUKEMIA & LYMPHOMA (2008)
Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells
Raghu Sinha et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2008)
Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival
Y. Wang et al.
ONCOGENE (2008)
Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells
John T. Pinto et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
The mTOR pathway in the control of protein synthesis
Xuemin Wang et al.
PHYSIOLOGY (2006)
Expression of mTOR signaling pathway markers in prostate cancer progression
Celeste L. Kremer et al.
PROSTATE (2006)
Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment
J Jozwiak et al.
MEDICINAL RESEARCH REVIEWS (2006)
Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis
K Yamaguchi et al.
ONCOGENE (2005)
Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells
HB Hu et al.
CLINICAL CANCER RESEARCH (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
LJ Johnston et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov et al.
CURRENT BIOLOGY (2004)
Share Paper
